Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds EF Hutton Reiterates Buy on Small Pharma, Maintains C$5 Price Target

EF Hutton Reiterates Buy on Small Pharma, Maintains C$5 Price Target

EF Hutton analyst Elemer Piros reiterates Small Pharma (TSXV:DMT) with a Buy and maintains C$5 price target.

byBenzinga Newsdesk

March 7, 2023

1 minute read

EF Hutton analyst Elemer Piros reiterates Small Pharma (TSXV:DMT) with a Buy and maintains C$5 price target.

HC Wainwright & Co. Maintains Neutral on Versus Systems, Raises Price Target to $2

By Benzinga Newsdesk

December 7, 7:39 AM

HC Wainwright & Co. analyst Scott Buck maintains Versus Systems (NASDAQ:VS) with a Neutral and raises the price target from $1.5 to $2.

Mizuho Maintains Buy on Microsoft, Lowers Price Target to $340

By Benzinga Newsdesk

July 19, 9:57 AM

Mizuho analyst Gregg Moskowitz maintains Microsoft (NASDAQ:MSFT) with a Buy and lowers the price target from $350 to $340.

MSFT

Essent: Q2 Earnings Insights

By Benzinga Insights

August 5, 7:08 AM

Essent Gr (NYSE:ESNT) reported its Q2 earnings results on Friday, August 5, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

ESNT

Analyst Ratings

Analyst Expectations for Unicycive Therapeutics’s Future

By Benzinga Insights

May 17, 8:02 AM

Within the last quarter, Unicycive Therapeutics (NASDAQ:UNCY) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

UNCY

EF Hutton Reiterates Buy on Small Pharma, Maintains C$5 Price Target

Related Posts

HC Wainwright & Co. Maintains Neutral on Versus Systems, Raises Price Target to $2

Mizuho Maintains Buy on Microsoft, Lowers Price Target to $340

Essent: Q2 Earnings Insights

Analyst Expectations for Unicycive Therapeutics’s Future